ATF4 and melanoma: It has been reported that MAPK inhibitor-resistant SK-MEL-28 cells have a decreased expression ratio of melanocyte-inducing transcription factor (MITF) to AXL receptor tyrosine kinase, a marker of targeted therapy resistance in melanoma [20], which is possibly driven by increased ATF4 expression [21].